S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
NASDAQ:AYLA

Ayala Pharmaceuticals News Headlines

$2.00
-0.05 (-2.44%)
(As of 05/13/2022 03:59 PM ET)
Add
Compare
Today's Range
$1.97
$2.30
50-Day Range
$2.00
$4.30
52-Week Range
$1.97
$14.95
Volume
15,600 shs
Average Volume
29,479 shs
Market Capitalization
$28.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.39
Get Ayala Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for AYLA and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Ayala Pharmaceuticals Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

AYLA
News Sentiment

1.29

0.48

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

AYLA Articles
This Week

3

0

AYLA Articles
Average Week



Ayala Pharmaceuticals (NASDAQ:AYLA) News Headlines Today

SourceHeadline
MarketBeat logoShort Interest in Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) Decreases By 63.6%
americanbankingnews.com - May 12 at 4:54 AM
MarketBeat logoShort Interest in Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) Expands By 33.3%
americanbankingnews.com - May 2 at 4:46 AM
finance.yahoo.com logoAyala Pharmaceuticals Announces Poster Presentation on AL101 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - April 27 at 1:49 PM
seekingalpha.com logoAyala Pharmaceuticals GAAP EPS of -$2.80, revenue of $3.5M
seekingalpha.com - March 30 at 9:51 PM
msn.com logoAyala Pharmaceuticals, Inc. (AYLA) Reports Q4 Loss, Tops Revenue Estimates
msn.com - March 28 at 7:10 PM
finance.yahoo.com logoAyala Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update
finance.yahoo.com - March 28 at 7:10 PM
finance.yahoo.com logoAyala Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference
finance.yahoo.com - March 9 at 9:00 AM
finance.yahoo.com logoAyala Pharmaceuticals (NASDAQ:AYLA) Will Have To Spend Its Cash Wisely
finance.yahoo.com - March 3 at 8:41 AM
finance.yahoo.com logoAyala Pharmaceuticals Announces Completion of Enrollment in Part A of RINGSIDE, a Pivotal Phase 2/3 Study of AL102 in Desmoid Tumors
finance.yahoo.com - February 23 at 12:20 PM
nasdaq.com logoAyala Pharmaceuticals, Inc. Common Stock (AYLA)
nasdaq.com - January 19 at 11:33 PM
finance.yahoo.com logoBuy These 2 Small-Cap Stocks to Double Your Investment, Say Analysts
finance.yahoo.com - January 17 at 6:40 PM
nasdaq.com logoAyala Pharmaceuticals Inc Shares Fall 4.6% Below Previous 52-Week Low - Market Mover
nasdaq.com - January 13 at 7:29 PM
nasdaq.com logoAyala Pharmaceuticals Inc Shares Fall 4.3% Below Previous 52-Week Low - Market Mover
nasdaq.com - January 7 at 11:31 PM
finance.yahoo.com logoAyala Pharmaceuticals Announces Key Business Objectives for 2022
finance.yahoo.com - January 4 at 12:27 PM
finance.yahoo.com logoHow Much Upside is Left in Ayala Pharmaceuticals, Inc. (AYLA)? Wall Street Analysts Think 116%
finance.yahoo.com - November 18 at 12:57 PM
finance.yahoo.com logoAyala Pharmaceuticals, Inc. (AYLA) Reports Q3 Loss, Misses Revenue Estimates
finance.yahoo.com - November 15 at 3:03 PM
finance.yahoo.com logoAyala Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
finance.yahoo.com - November 15 at 8:35 AM
finance.yahoo.com logoAyala Pharmaceuticals to Present at Jefferies London Healthcare Conference
finance.yahoo.com - November 10 at 8:20 AM
nasdaq.com logoEarnings Preview: Ayala Pharmaceuticals, Inc. (AYLA) Q3 Earnings Expected to Decline
nasdaq.com - November 9 at 5:07 PM
barrons.com logoAyala Pharmaceuticals Inc.
barrons.com - October 7 at 11:31 PM
finance.yahoo.com logoAyala Pharma Unveils New Interim Data From Rare Cancer Trial With AL101
finance.yahoo.com - September 16 at 8:44 PM
finance.yahoo.com logoAyala Pharmaceuticals Presents Preliminary Clinical Data from the Ongoing Phase 2 ACCURACY Trial and Announces Pre-Clinical Proof of Concept Data for Enhanced Activity of AL101 in Combination with Approved Cancer Therapies in ACC
finance.yahoo.com - September 16 at 10:32 AM
nasdaq.com logoInvestors in Ayala Pharmaceuticals (NASDAQ:AYLA) have made a respectable return of 51% over the past year
nasdaq.com - September 7 at 8:27 AM
finance.yahoo.com logoAyala Pharmaceuticals to Present Clinical Data from Ongoing Phase 2 ACCURACY Trial and New Preclinical Results from Combination Study of AL101 at the European Society for Medical Oncology (ESMO) Virtual Congress 2021
finance.yahoo.com - September 1 at 8:54 AM
finance.yahoo.com logoAyala Pharmaceuticals, Inc. (AYLA) Reports Q2 Loss, Lags Revenue Estimates
finance.yahoo.com - August 13 at 3:21 PM
finance.yahoo.com logoWill Ayala Pharmaceuticals, Inc. (AYLA) Report Negative Q2 Earnings? What You Should Know
finance.yahoo.com - August 5 at 8:03 PM
finance.yahoo.com logoWe Think Ayala Pharmaceuticals (NASDAQ:AYLA) Needs To Drive Business Growth Carefully
finance.yahoo.com - July 29 at 9:58 AM
finance.yahoo.com logoIs AYLA Stock A Buy Here?
finance.yahoo.com - June 18 at 2:34 PM
finance.yahoo.com logoAyala Pharmaceuticals, Inc. (AYLA) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 14 at 2:22 PM
finance.yahoo.com logoAyala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
finance.yahoo.com - May 14 at 9:21 AM
finance.yahoo.com logoAyala Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of AL102 in Combination with BCMA Targeting Agent, WVT078, in Patients with relapsed/refractory Multiple Myeloma
finance.yahoo.com - April 21 at 12:34 PM
finance.yahoo.com logoAyala Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Business Update
finance.yahoo.com - March 25 at 9:10 AM
finance.yahoo.com logoAyala Pharmaceuticals Inc (AYLA) President & CEO Roni Mamluk Sold $617,137 of Shares
finance.yahoo.com - February 24 at 11:15 PM
bizjournals.com logoAyala Pharmaceuticals raises $25M from private stock sale
bizjournals.com - February 24 at 6:15 PM
finance.yahoo.com logoAyala Pharmaceuticals To Raise $25M Via Private Stock Placement; Shares Pop 16%
finance.yahoo.com - February 22 at 1:13 PM
finance.yahoo.com logoAyala Pharmaceuticals Raises $25M Via Equity To Fund AL102 Development In Connective Tissue Tumors
finance.yahoo.com - February 19 at 2:34 PM
finance.yahoo.com logoCompanies Like Ayala Pharmaceuticals (NASDAQ:AYLA) Are In A Position To Invest In Growth
finance.yahoo.com - February 19 at 9:33 AM
nasdaq.com logoACIU & Alzheimer's Vaccine, GNMK Rallies, ESSA's Prostate Cancer Drug On Track, MNPR On Watch
nasdaq.com - February 12 at 7:35 AM
nasdaq.com logoNVAX's Covid Jab Shows 89.3% Efficacy In UK Trial, AZRX Awaits Data, FDA Lifts Hold On BLCM Trial
nasdaq.com - January 29 at 2:14 AM
finance.yahoo.com logoAyala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 for the Treatment of Patients with Notch-Activated Triple Negative Breast Cancer
finance.yahoo.com - January 28 at 11:10 AM
finance.yahoo.com logoAyala Pharmaceuticals to Present at Noble Capital Markets 17th Annual Small & Microcap Virtual Investor Conference
finance.yahoo.com - January 13 at 8:55 PM
finance.yahoo.com logoAyala Pharmaceuticals to Present at the Virtual H.C. Wainwright Bioconnect Conference
finance.yahoo.com - January 5 at 11:57 AM
finance.yahoo.com logoAyala Pharmaceuticals to Accelerate Development of AL102 for the Treatment of Desmoid Tumors in Pivotal Phase 2/3 Study
finance.yahoo.com - January 4 at 12:53 PM
reuters.com logoAyala Pharmaceuticals Inc
reuters.com - December 16 at 7:44 AM
nasdaq.com logoGrowth Investors: Industry Analysts Just Upgraded Their Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) Revenue Forecasts By 64%
nasdaq.com - November 20 at 10:08 AM
seekingalpha.com logoAyala Pharmaceuticals EPS misses by $0.03, beats on revenue
seekingalpha.com - November 19 at 8:40 AM
finance.yahoo.com logoAyala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update
finance.yahoo.com - November 17 at 9:49 AM
finance.yahoo.com logoAyala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
finance.yahoo.com - November 5 at 9:48 AM
seekingalpha.com logoAyala Pharma under pressure on underwhelming AL101 data in type of cancer affecting the glandular tissues
seekingalpha.com - September 18 at 1:46 PM
finance.yahoo.com logoAyala Pharmaceuticals Presents Positive Interim Data from Phase 2 ACCURACY Trial of AL101 for the treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma with Notch Activating Mutations at ESMO 2020
finance.yahoo.com - September 18 at 8:45 AM
Get Ayala Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for AYLA and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.